Synthesis, Charatcterization and Preclinical Studies of Tartgeted Photo-Dynamic Therapy Agents Activated in the Tissue Transparency Window

Jean R. Starkey,Fanging Meng,Aijun Gong,Britney L. Moss,Aleksandre Rebane,Mikhail Drobizhev,Charles W. Spangler

IF: 11.2

2005-01-01

Cancer Research

Abstract:4740 Currently approved photo-dynamic therapy (PDT) agents are limited by their activation wavelengths which fall short of the tissue transparency window (700-1000 nm). With these agents, it is only feasible to treat tumors up 2-3 mm below the skin, or the activating light sources must be introduced into the tissue of interest. Other limitations are poor selectivity for tumor tissue and long residence times leading to extended light sensitivity. We have designed novel modular PDT agents that can be activated in the tissue transparency window, are targeted to the tumor tissue, and possess a module (indodicarbocyanine) for near infrared fluorescence (IR) imaging. Two-photon excited fluorescence has been demonstrated for these compounds at depths of 3 cm in highly scattering tissue phantoms. A protocol for evaluating the ability of PDT to kill tumor cells at specific depths in a tissue phantom was developed and the model was validated using Photofrin® treated MDA-MB-231 cells. Using in vivo near IR fluorescence imaging of SCID mice bearing MDA-MB-231 human breast cancer tumors, we validated the ability of the compounds to be targeted by the octreoate peptide to overexpressed somatostatin 2 (SST2) receptors on the cancer cells. Drug clearance was imaged occurring via the gall bladder and intestinal route, and the in vivo imaging studies indicated that there would likely be a good window of time for therapeutic activation of the compound. Since our compounds are the first ones to have a 2-photon cross section large enough to be considered for therapeutic PDT, appropriate protocols needed to be developed for many of the preclinical studies, and, while we envision any clinical application encompassing the ability to raster the near IR laser beam(s), until such a system is developed, we have adapted a motorized X,Y,Z stage to raster the target cells/tumor bearing mouse. Our initial results using this system will be presented. Supported by a grant from the Montana Board of Research and Commercialization and Technology.